Skip to content

Study · Observational study · n = 84 · 2020

3 results

Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study.

Lee S, Lee HH, Lee Y, Lee J

Journal of rehabilitation medicine27 Feb 2020Cited by 7 (Europe PMC)

PMID32057086 (opens in a new tab)DOI10.2340/16501977-2654 (opens in a new tab)PepBankPUB-32057086
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with acquired brain injury, added Cerebrolysin was linked to greater CRS-R improvement than amantadine alone.

    In plain wordsIn patients with brain injury, added Cerebrolysin was linked to greater consciousness score improvement than amantadine alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCRS-R score change
    Study

    n = 84

    Comparator
    Amantadine alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    The degree of change in CRS-R and the proportion of patients in the disorders of consciousness category showing a change was higher in the dual regimen group than in the single regimen group.
    3 context sentences
    Summary · context
    The medical records of patients diagnosed with disorders of consciousness after acquired brain injury were reviewed.
    Summary · context
    The patients were categorized into 2 groups: single regimen (amantadine only) and dual regimen (amantadine plus cerebrolysin).
    Summary · context
    The patients' conscious states were assessed using the Coma Recovery Scale-Revised (CRS-R) before, and after 4 weeks of drug administration.
  2. 02HumanObservational studyEfficacy outcome

    In patients with acquired brain injury, added Cerebrolysin was linked to a higher proportion with consciousness category change than amantadine alone.

    In plain wordsIn patients with brain injury, added Cerebrolysin was linked to more consciousness category changes than amantadine alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseProportion with consciousness category change
    Study

    n = 84

    Comparator
    Amantadine alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    The degree of change in CRS-R and the proportion of patients in the disorders of consciousness category showing a change was higher in the dual regimen group than in the single regimen group.
    3 context sentences
    Summary · context
    The medical records of patients diagnosed with disorders of consciousness after acquired brain injury were reviewed.
    Summary · context
    The patients were categorized into 2 groups: single regimen (amantadine only) and dual regimen (amantadine plus cerebrolysin).
    Summary · context
    The patients' conscious states were assessed using the Coma Recovery Scale-Revised (CRS-R) before, and after 4 weeks of drug administration.
  3. 03HumanObservational studyEfficacy outcome

    In initially vegetative or minimally conscious state minus patients, added Cerebrolysin was linked to greater CRS-R increases than amantadine alone.

    In plain wordsIn initially vegetative or minimally conscious state minus patients, added Cerebrolysin was linked to greater consciousness score increases than amantadine alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCRS-R change in prolonged vegetative or minimally conscious state minus subgroup
    Study

    n: not reported in source

    Comparator
    Amantadine alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Analysis of patients who had initially been in a prolonged vegetative state or minimally conscious state minus before administration showed that the patients in the dual regimen group had greater increases in CRS-R scores than those in the single regimen group.
    3 context sentences
    Summary · context
    The medical records of patients diagnosed with disorders of consciousness after acquired brain injury were reviewed.
    Summary · context
    The patients were categorized into 2 groups: single regimen (amantadine only) and dual regimen (amantadine plus cerebrolysin).
    Summary · context
    The patients' conscious states were assessed using the Coma Recovery Scale-Revised (CRS-R) before, and after 4 weeks of drug administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT06052787

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

Ain Shams Universityn = 1501 Sept 2023 to 1 Aug 2025

Traumatic Brain Injury

Trial pageClinicalTrials.govUpdated 19 Nov 2025
RecruitingPhase 4NCT04427241

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Konkuk University Medical Centern = 121 Jun 2023 to est. 31 Dec 2026

Disorder of Consciousness · Hemorrhagic Stroke

Trial pageClinicalTrials.govUpdated 11 May 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.